Acumen Pharmaceuticals (ABOS) Change in Acquisitions & Divestments (2022 - 2026)

Acumen Pharmaceuticals (ABOS) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $27.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 57.67% year-over-year to $27.0 million; the trailing twelve-month figure through Mar 2026 stood at $135.3 million (down 45.12% YoY), and the FY2025 full-year result was $172.1 million, down 21.34% from the prior year.
• Change in Acquisitions & Divestments advanced to $27.0 million in Q1 2026, from $26.2 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $88.4 million in Q3 2024 to a low of $4.0 million in Q1 2022.
• A 5-year average of $34.0 million and a median of $34.7 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments jumped 347.44% in 2024 and sank 57.67% in 2026, its largest moves.
• Tracing ABOS's Change in Acquisitions & Divestments over 5 years: stood at $9.0 million in 2022, then surged by 155.38% to $23.0 million in 2023, then soared by 94.76% to $44.8 million in 2024, then plunged by 41.36% to $26.2 million in 2025, then advanced by 2.92% to $27.0 million in 2026.
• Business Quant data shows ABOS's Change in Acquisitions & Divestments at $27.0 million in Q1 2026, $26.2 million in Q4 2025, and $40.5 million in Q3 2025.